Literature DB >> 8200640

TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis.

M T Jennings1, I T Kaariainen, L Gold, R J Maciunas, P A Commers.   

Abstract

Our previous investigations of transforming growth factor types beta 1 and beta 2 (TGF beta s) showed negative or positive autocrine growth regulation of gliomas in vitro. Near-diploid gliomas were inhibited by the TGF beta s, whereas a stimulatory response correlated with progressive anaplasia and karyotypic divergence. We have tested the hypothesis that cytogenetic aberrations may be associated with conversion of TGF beta autoregulation from inhibitory to stimulatory among other cultured neuroectodermal tumors. Anchorage-independent growth and karyotypic aberrations supported the malignant nature in vitro of two medulloblastoma (MBL), two primitive neuroectodermal tumor (PNET), and two ependymoma (EPD) cultures. Transforming growth factor type beta 1 and/or TGF beta 2 RNA was evident by Northern blot analysis among these cell cultures. By radioreceptor assay active TGF beta was present in conditioned medium in concentrations of 0 to 14 ng/mL, whereas the total amount of active and latent TGF beta secreted was in the range of 3 to 118 ng/mL. Expression of the TGF beta radioreceptor (TGF beta-R) types I and II was shown by cross-linking assay. Responses to exogenous TGF beta were determined by [3H]-thymidine incorporation, cell counts, and anchorage-independent clonogenicity. Exogenous TGF beta was growth inhibitory for the near-diploid MBL, PNET, and EPD in vitro, as well as antagonistic to the mitogenic effect of epidermal growth factor (EGF) and insulin. In contrast, MBL, PNET, and EPD with a hyperdiploid subpopulation were stimulated to proliferate in monolayer culture or soft agar by TGF beta 1 and TGF beta 2. The growth response did not correlate with TGF beta-R type. Autocrine regulation was supported by antibody neutralization experiments performed with quiescent cells in the absence of exogenous TGF beta. Anti-TGF beta antisera enhanced the growth of TGF beta-inhibited cultures, whereas the TGF beta-stimulated cultures were inhibited by the antisera. Karyotypic divergence seemed to predict response as MBL, PNET, and EPD with hyperdiploid elements exhibited autocrine TGF beta-stimulation. In contrast, the near-diploid cultures were inhibited by the TGF beta s. By analogy with the gliomas, conversion of TGF beta autocrine regulation from inhibition to stimulation may be a late progression marker of anaplasia among MBL, PNET, and EPD. Secretion of this TGF, which serves both as a mitogen and immunosuppressive agent may contribute to the adverse prognosis of hyperdiploid neuroectodermal neoplasms of the central nervous system (CNS).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200640     DOI: 10.1016/0046-8177(94)90118-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor.

Authors:  M T Jennings; C E Hart; P A Commers; J A Whitlock; D Martincic; R J Maciunas; P L Moots; T M Shehab
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

2.  Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall.

Authors:  Shengwen Calvin Li; Long T Vu; Hector W Ho; Hong Zhen Yin; Vic Keschrumrus; Qiang Lu; Jun Wang; Heying Zhang; Zhiwei Ma; Alexander Stover; John H Weiss; Philip H Schwartz; William G Loudon
Journal:  Cancer Cell Int       Date:  2012-09-20       Impact factor: 5.722

3.  Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.

Authors:  Su Guan; Ruijun Shen; Tiffany Lafortune; Ningyi Tiao; Peter Houghton; W K Alfred Yung; Dimpy Koul
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

Review 4.  The role of transforming growth factor beta in glioma progression.

Authors:  M T Jennings; J A Pietenpol
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.

Authors:  Litian Yu; Patricia A Baxter; Horatiu Voicu; Sivashankarappa Gurusiddappa; Yijue Zhao; Adekunle Adesina; Tsz-Kwong Man; Qin Shu; Yu-Jing Zhang; Xiu-Mei Zhao; Jack M Su; Lazlo Perlaky; Robert Dauser; Murali Chintagumpala; Ching C Lau; Susan M Blaney; Pulivarthi H Rao; Hon-Chiu Eastwood Leung; Xiao-Nan Li
Journal:  Neuro Oncol       Date:  2010-02-08       Impact factor: 12.300

6.  Identification of microRNAs as potential prognostic markers in ependymoma.

Authors:  Fabricio F Costa; Jared M Bischof; Elio F Vanin; Rishi R Lulla; Min Wang; Simone T Sredni; Veena Rajaram; Maria de Fátima Bonaldo; Deli Wang; Stewart Goldman; Tadanori Tomita; Marcelo B Soares
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 7.  Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.

Authors:  Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares
Journal:  Curr Treat Options Oncol       Date:  2021-07-30

8.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

9.  Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.

Authors:  Allison B Powell; Sridevi Yadavilli; Devin Saunders; Stacey Van Pelt; Elizabeth Chorvinsky; Rachel A Burga; Shuroug Albihani; Patrick J Hanley; Zhenhua Xu; Yanxin Pei; Eric S Yvon; Eugene I Hwang; Catherine M Bollard; Javad Nazarian; Conrad Russell Y Cruz
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.